newsfilter
← Latest News
GlobeNewswire·

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-yearFY 2026 net product revenue guidance increased to $140 - $150 millionGross